Ciara Curtin writes science features for GenomeWeb and is the editor of the Daily Scan and Careers blogs.
A Johns Hopkins-based team said a panel of bispecific antibodies could be developed to target a range of common cancer driver mutations.
A study presented at the NSGC annual meeting found that tumor analysis and germline testing yielded discordant results in almost a quarter of cases.
The study, presented at the NSGC annual conference last week, supports the broader use of panel testing for cancer patients suspected of hereditary disease.
Fred Hutchinson Cancer Research Center investigators engineered T cells to recognize a protein expressed by acute myeloid leukemia cells with a CBFB-MYH11 gene fusion.
Initial data on the PARIS test, combining functional drug testing and DNA sequencing, showed concordance between its predictions and patients' treatment responses.
The analysis presented at the AACR Virtual Annual Meeting confirmed the effectiveness of the TRK inhibitor to treat cancer patients with NTRK gene fusions.
Additional analyses found the talazoparib arm reported a better quality of life and a limited effect of broader tumor genomic markers on clinical benefit or progression-free survival.
The large BRCA1 deletion, which was not captured by initial genetic testing, might be the reason for the patient's exceptional response to a PARP inhibitor.
The Swedish firm Biovica said this and additional studies will form the basis of a US Food and Drug Administration submission for its test measuring thymidine kinase-1.
The organoids could be grown to contain cellular features of the original tissue samples, enabling them to better mimic what occurs in the body than two-dimensional cultures.